Virginia Mason Franciscan Health is relentlessly devoted to providing exceptional health care—which is why we conduct clinical studies to improve the way we diagnose, treat and prevent disease.
Our cancer experts collaborate with Benaroya Research Institute and the Center for Digestive Health to offer colon cancer studies. Our trials include the use of chemotherapy, radiation and targeted therapies, as well quality of life and symptom management trials.
Virginia Mason Franciscan Health has a long-standing partnership with Benaroya Research Institute, which is a national leader in immunology and immune tolerance research. Our research program offers clinical trials for Crohn’s disease and ulcerative colitis in conjunction with the Center for Digestive Health and Benaroya Research Institute.
Learn more about our current colon cancer clinical trials:
PACES: Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III
A Randomized Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors Compared to a Healthy Living Education Control: A Feasibility and Preliminary Efficacy Study
A Pilot Protocol Evaluating Safety of the Medtronic Pump and Codman Catheter for the Delivery of Hepatic Arterial Infusion (HA I) Chemotherapy in patients with advanced Colorectal Carcinoma or Cholangiocarcinoma
Learn more about our current IBD clinical trials for Crohn’s disease and ulcerative colitis.
A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicenter Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks
A Phase 3, Multicenter, Randomized, Efficacy Assessor-Blinded Study of Risankizumab Compared to Ustekinumab for the Treatment of Adult Subjects with Moderate to Severe Crohn’s Disease Who Have Failed Anti-TNF Therapy